The lower wells contained various combinations of medium/cells/bFGF: (1) ASC medium (DMEM); (2) ASC medium (DMEM) plus 10 ng/ml bFGF; (3) non-T2DM ASCs; (4) subcutaneous T2DM ASCs; (5) subcutaneous T2DM ASCs treated for 9 days with bFGF; (6) visceral T2DM ASCs; and (7) visceral T2DM ASCs treated for 9 days with bFGF. Here, FGF2 is linked to type 2 diabetes mellitus.